View in EDS HTML Full Text PDF Full Text

Interaction between baseline BMI and baseline disease severity predicts greater improvement in negative symptoms in first-episode schizophrenia.

Saved in:
Bibliographic Details
Title: Interaction between baseline BMI and baseline disease severity predicts greater improvement in negative symptoms in first-episode schizophrenia.
Authors: Sun, Xiaobing (AUTHOR), He, Ruiqing (AUTHOR), Xiao, Yuan (AUTHOR), Xiu, Meihong (AUTHOR), Sun, Maodi (AUTHOR), Wu, Fengchun (AUTHOR), Zhang, Xiang Yang (AUTHOR)
Source: European Archives of Psychiatry & Clinical Neuroscience. Sep2024, Vol. 274 Issue 6, p1327-1332. 6p.
Subjects: Body mass index, Antipsychotic agents, Regression analysis, Linear statistical models, People with schizophrenia
Abstract: Several studies have reported that baseline symptom severity in patients with schizophrenia (SCZ) is associated with the efficacy of antipsychotic medication. Overweight/obesity is common in SCZ and has also been reported to be correlated with therapeutic response to antipsychotics. This study aimed to evaluate whether baseline body mass index (BMI) and disease severity were associated with improvements in negative symptoms in patients with first-episode and medication-naïve (FEMN) SCZ. A total of 241 FEMN patients were recruited in this study and treated with oral risperidone over 3 months. Clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) and BMI was assessed at baseline and 3-month follow-up. We found that baseline BMI was correlated with the baseline severity of symptoms. Baseline BMI or baseline disease severity was associated with improvement in negative symptoms after 3 months of treatment. Linear regression analysis indicated that the interaction of BMI and disease severity at baseline was associated with improvement in negative symptoms in the early stage of SCZ after controlling for sex, age, and dose of risperidone. Our study suggests that the interaction of baseline BMI and disease severity may play a role in predicting negative symptom improvement after 3 months of risperidone treatment. [ABSTRACT FROM AUTHOR]
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 179325820
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Interaction between baseline BMI and baseline disease severity predicts greater improvement in negative symptoms in first-episode schizophrenia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Sun%2C+Xiaobing%22">Sun, Xiaobing</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22He%2C+Ruiqing%22">He, Ruiqing</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xiao%2C+Yuan%22">Xiao, Yuan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xiu%2C+Meihong%22">Xiu, Meihong</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+Maodi%22">Sun, Maodi</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+Fengchun%22">Wu, Fengchun</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Xiang+Yang%22">Zhang, Xiang Yang</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22">European Archives of Psychiatry & Clinical Neuroscience</searchLink>. Sep2024, Vol. 274 Issue 6, p1327-1332. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Body+mass+index%22">Body mass index</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Regression+analysis%22">Regression analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Linear+statistical+models%22">Linear statistical models</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+schizophrenia%22">People with schizophrenia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Several studies have reported that baseline symptom severity in patients with schizophrenia (SCZ) is associated with the efficacy of antipsychotic medication. Overweight/obesity is common in SCZ and has also been reported to be correlated with therapeutic response to antipsychotics. This study aimed to evaluate whether baseline body mass index (BMI) and disease severity were associated with improvements in negative symptoms in patients with first-episode and medication-naïve (FEMN) SCZ. A total of 241 FEMN patients were recruited in this study and treated with oral risperidone over 3 months. Clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) and BMI was assessed at baseline and 3-month follow-up. We found that baseline BMI was correlated with the baseline severity of symptoms. Baseline BMI or baseline disease severity was associated with improvement in negative symptoms after 3 months of treatment. Linear regression analysis indicated that the interaction of BMI and disease severity at baseline was associated with improvement in negative symptoms in the early stage of SCZ after controlling for sex, age, and dose of risperidone. Our study suggests that the interaction of baseline BMI and disease severity may play a role in predicting negative symptom improvement after 3 months of risperidone treatment. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=179325820
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00406-024-01763-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 1327
    Subjects:
      – SubjectFull: Body mass index
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Regression analysis
        Type: general
      – SubjectFull: Linear statistical models
        Type: general
      – SubjectFull: People with schizophrenia
        Type: general
    Titles:
      – TitleFull: Interaction between baseline BMI and baseline disease severity predicts greater improvement in negative symptoms in first-episode schizophrenia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sun, Xiaobing
      – PersonEntity:
          Name:
            NameFull: He, Ruiqing
      – PersonEntity:
          Name:
            NameFull: Xiao, Yuan
      – PersonEntity:
          Name:
            NameFull: Xiu, Meihong
      – PersonEntity:
          Name:
            NameFull: Sun, Maodi
      – PersonEntity:
          Name:
            NameFull: Wu, Fengchun
      – PersonEntity:
          Name:
            NameFull: Zhang, Xiang Yang
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09401334
          Numbering:
            – Type: volume
              Value: 274
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: European Archives of Psychiatry & Clinical Neuroscience
              Type: main
ResultId 1